Research progress on the role of IDO signaling pathway in radiotherapy for non-small cell lung cancer

VernacularTitle:IDO信号通路在非小细胞肺癌放疗的应用进展
Author: Linfang WU ¹ ; Chunyu WANG ; Yufan YANG ; Nan BI ; Lyuhua WANG
Author Information

1. 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院放疗科，北京　100021
Keywords: Indoleamine 2, 3-dioxygenase; Neoplasm, non-small cell lung/radiotherapy; Immune
From: Chinese Journal of Radiation Oncology 2022;31(2):219-222
CountryChina
Language:Chinese
Abstract: Indoleamine 2, 3-dioxygenase (IDO) is one of the rate-limiting enzymes that degrade tryptophan (Trp) into kynurenine (Kyn). Inflammatory factor IFN-γ mediates tumor′s immune escape by activating the IDO signaling pathway, upregulating theKyn/Trp (K/T ratio) and suppressing the activity of both CD 8+T and regulatory T cells. Radiotherapy plays a major role in treating non-small cell lung cancer. It not only bi-directionally regulates immune response of the host, but also collaborates with immunosuppressive agents to kill tumors. Meanwhile, immune status of the host can affect the therapeutic effect of radiotherapy. In recent years, studies have shown that IDO activity levels change before and after radiotherapy and is related to clinical prognosis. Nevertheless, relevant mechanism remains unclear. This article aims to elucidate the application of IDO signaling pathway in radiotherapy for non-small cell lung cancer.